Psoriatic Arthritis
Conference Coverage
Debate: Should biologics be used for milder cases of psoriasis?
The decision to use a biologic should hinge on how badly patients and their quality of life are affected, Dr. Langley said.
Feature
Boosting the presence of darker skin in rheumatology education
Doctors are beginning to address educational gaps in rheumatologists’ exposure to rheumatic and musculoskeletal diseases in people with darker...
From the Journals
Most patients with chronic inflammatory diseases have sufficient response to COVID-19 vaccination
A preprint publication of a study of 133 people with chronic inflammatory disease and 53 controls shows that those with CID mount immune responses...
Military Dermatology
Apremilast Uses and Relevance to the Military
Apremilast is a versatile and easy-to-use therapeutic option for treatment of psoriasis and psoriatic arthritis. Dermatologists should consider...
From the Journals
Researchers stress importance of second COVID-19 vaccine dose for infliximab users
Significantly lower antibody concentrations seen after a first dose of the Pfizer or AstraZeneca vaccine in users of infliximab vs. vedolizumab...
Conference Coverage
Bimekizumab superior to adalimumab in head-to-head psoriasis study
The response to bimekizumab was notably fast.
Conference Coverage
Experts highlight recent breakthroughs in psoriatic arthritis
Signal of possible gender disparity in PsA response to biologics sparks questions.
Conference Coverage
Checkpoint inhibitor–induced rheumatic complications often arise late
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
Conference Coverage
To improve psoriatic arthritis outcomes, address common comorbidities
Depression and obesity are associated with poor treatment response in PsA.
Conference Coverage
Recent psoriasis pathophysiology insights carry treatment implications
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
From the Journals
Methotrexate-associated hepatotoxicity risk differs between psoriasis, PsA, and RA patients
When results were adjusted with Cox regression analyses, the psoriasis group had a significantly increased risk compared with the RA group with...